Research programme - gene editing therapeutics - Intellia Therapeutics/ Regeneron Pharmaceuticals

Drug Profile

Research programme - gene editing therapeutics - Intellia Therapeutics/ Regeneron Pharmaceuticals

Latest Information Update: 23 Aug 2016

Price : $50

At a glance

  • Originator Intellia Therapeutics
  • Developer Intellia Therapeutics; Regeneron Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyloidosis

Most Recent Events

  • 04 Aug 2016 Intellia Therapeutics and Regeneron Pharmaceuticals plan IND enabling studies for Amyloidosis
  • 11 Apr 2016 Early research in Amyloidosis in USA (unspecified route)
  • 11 Apr 2016 Regeneron Pharmaceuticals enters into collaboration and licensing agreements with Intellia Therapeutics to co-discover and co-develop the application of CRISPR/Cas therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top